Therapeutic targeting of MYCN oncoprotein stability in neuroblastoma

神经母细胞瘤中 MYCN 癌蛋白稳定性的治疗靶向

• 批准号: nhmrc : 1125171
• 负责人: Dr Belamy Cheung
• 金额: $ 40.27万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-targeting-mycn-stability-neuroblastoma/947524
• 关键词: Therapeutic; targeting; MYCN; oncoprotein; stability

A high level of MYCN protein is a major indicator of aggressive neuroblastoma (NB) but unfortunately there have been many barriers to the design of targeted therapies. We have identified a protein called PA2G4 which is a cofactor for MYCN in promoting cancer cell growth. We have developed a compound which inhibits PA2G4 and MYCN protein levels and reduces tumour growth. We will examine how PA2G4 cause aggressive tumour characteristics and test new methods to block PA2G4.

高水平的MYCN蛋白是侵袭性神经母细胞瘤（NB）的主要指标，但不幸的是，靶向疗法的设计存在许多障碍。我们已经确定了一种称为PA2G4的蛋白质，它是MYCN促进癌细胞生长的辅助因子。我们已经开发出一种化合物，可以抑制PA2G4和MYCN蛋白水平并减少肿瘤生长。我们将研究PA2G4如何导致侵袭性肿瘤特征，并测试阻断PA2G4的新方法。